David P. Nunes, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Gastroenterology Section

MBBCh, Trinity College



Expertise includes: Clinical liver disease - interest in viral hepatitis; Evaluation and management of liver lesions.

Active Staff Privileges
Boston Medical Center
Medicine




A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon alpha-2a (Pegasys)
11/01/2011 - 12/31/2012 (PI)
Gilead Sciences, Inc.

A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon alpha-2a (Pegasys)
11/01/2011 - 12/31/2012 (PI)
Gilead Sciences, Inc.

A Study to Describe the Safety and Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics with Chronic Hepatitis B Virus (HBV) Infection who are Nucleoside-Naive
10/17/2006 - 10/16/2008 (PI)
Bristol-Myers Squibb

A Randomized, Placebo Controlled, Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of NOV-205 in Chronic Viral Hepatitis C Subjects (Genotype 1) who have failed Treatment with Pegylated Interferon plus Ribavirin
01/23/2007 - 01/22/2008 (PI)
Novelos Therapeutics, Inc.

Phase II Study Of Long Term Peg Intron Fpr Patients Who Have Failed to Respond to Rebetron/Interferon with Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C.
05/11/2001 - 05/31/2005 (PI)
Schering Corporation

Evaluating the Erythropoietic Response to Anemia in HCV
01/01/2002 - 12/31/2003 (PI)
Ortho Biotech Inc

Comparison of PEG Interferon Alfa 2b Plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects
12/01/2001 - 11/30/2003 (PI)
Integrated Therapeutics Group

A Prospective, Randomized, Multicenter, Open Label Comparative Safety Study of Pegasys vs. Pegasys Plus Ribavirin Treatment vs. a Twelve Treatment Delay in Patients with Chronic Hepatitis C
02/06/2001 - 12/31/2002 (PI)
Roche Laboratories Inc

A Randomized, Partially Blinded, Multicenter, Phase II Study Investigating the Efficacy and Safety of Pegasys and Pegasys with Ribavirin in Treatment Naive Patients with Chronic Hepatitis C Coinfected with Human Immunodeficiency Virus
01/18/2001 - 01/31/2002 (PI)
Roche Laboratories Inc




Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Baranoski AS, Cotton D, Heeren T, Nunes D, Kubiak RW, Horsburgh CR. Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men. Open Forum Infect Dis. 2016 Jan; 3(1):ofv214.View Related Profiles. PMID: 26955643; DOI: 10.1093/ofid/ofv214;.
  2. Anderson JP, Horsburgh CR, Williams PL, Tchetgen Tchetgen EJ, Nunes D, Cotton D, Seage GR. CD4 recovery on antiretroviral therapy is associated with decreased progression to liver disease among hepatitis C virus-infected injecting drug users. Open Forum Infect Dis. 2015 Jan; 2(1):ofv019.View Related Profiles. PMID: 26034769; DOI: 10.1093/ofid/ofv019;.
  3. Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, Tsui JI. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction. 2014 Jan; 109(1):62-70.View Related Profiles. PMID: 24112091; PMCID: PMC3947001; DOI: 10.1111/add.12367;.
  4. Okafor PN, Nunes DP, Farraye FA. Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered? Inflamm Bowel Dis. 2013 Jul; 19(8):1764-71.View Related Profiles. PMID: 23615530; DOI: 10.1097/MIB.0b013e318281f562;.
  5. Fuster D, Tsui JI, Cheng DM, Quinn EK, Armah KA, Nunes D, Freiberg MS, Samet JH. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. AIDS Res Hum Retroviruses. 2013 Aug; 29(8):1110-6.View Related Profiles. PMID: 23601055; PMCID: PMC3715787; DOI: 10.1089/AID.2012.0348;.
  6. Fuster D, Tsui JI, Cheng DM, Quinn EK, Bridden C, Nunes D, Libman H, Saitz R, Samet JH. Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. Alcohol Clin Exp Res. 2013 Sep; 37(9):1527-35.View Related Profiles. PMID: 23647488; PMCID: PMC3758457; DOI: 10.1111/acer.12129;.
  7. Pereira C, Yalçin A, Cretich M, Chiari M, Unlü MS, Nunes D, Bergstein DA. Synergetic chemiluminescence and label-free dual detection for developing a hepatitis protein array. J Immunol Methods. 2011 Aug 31; 371(1-2):159-64. PMID: 21718699; PMCID: PMC3152660; DOI: 10.1016/j.jim.2011.06.004;.
  8. Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, Koziel MJ, Graham C, Tumilty S, Skolnik P, Stuver S, Horsburgh CR, Cotton D. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol. 2010 Jun; 105(6):1346-53.View Related Profiles. PMID: 20179698; DOI: 10.1038/ajg.2009.746;.
  9. Pungpapong S, Nunes DP, Krishna M, Nakhleh R, Chambers K, Ghabril M, Dickson RC, Hughes CB, Steers J, Nguyen JH, Keaveny AP. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl. 2008 Sep; 14(9):1294-302. PMID: 18756457; DOI: 10.1002/lt.21508;.
  10. Sullivan LE, Saitz R, Cheng DM, Libman H, Nunes D, Samet JH. The impact of alcohol use on depressive symptoms in human immunodeficiency virus-infected patients. Addiction. 2008 Sep; 103(9):1461-7.View Related Profiles. PMID: 18637000; PMCID: PMC2661114; DOI: 10.1111/j.1360-0443.2008.02245.x;.
Showing 10 of 50 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 50 publications over 18 distinct years, with a maximum of 5 publications in 2007

YearPublications
19892
19953
19961
19974
19984
19993
20003
20022
20031
20043
20054
20063
20075
20084
20101
20111
20134
20152
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Hepatitis B
Hepatitis C
Liver fibrosis
Contact for Mentoring:


85 E. Concord St
Boston MA 02118
Google Map


Nunes's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department